sensitivity comparable with other HPLC methods for methyixanthines (11, 12) and is suitable for both therapeutic drug monitoring and pharmacokinetics studies. Because the specificity of the assay, in the absence of any extraction procedure, relies on the chromatographic separation, we have given special care to examining the possibility of co-eluting peaks. Theophylline and caffeine are well resolved from dyphylline and doxofylline, and none of 76 drugs we examined (Table 1) has shown significant interferences.
4.

Kester
We assessed the performanceof three commercially available polyclonal immunoassays for apparent cyclosponne in 120 whole-blood specimens collected from transplant recipients just before their next dose of cyclospormne (C5A). The assays were (a) Abbott's TDx fluorescent polarization immunoassay for GsA and its metabolites in whole blood; (b) the Sandoz radioimmunoassay (RIA); and (C) lncstar's CycloTrac RIA. Mean respective CVs were 3.8%, 9.3%, and 24.3%. Analyticalrecovery was nearly 100% for concentrations up to 1000 ug/L for lncstar and up to 1500 pg/L for Abbott and Sandoz; linearity was compromised at greater concentrations. We also quantified the parent C5A concentrations by HPLC. Moreover, to follow day-to-day fluctuations in patients' "cyclosporine" concentrations with each method and to assess the impact these differences have on interpre-the established trend. Biases observed among the assays can be explained in part by the nonspecific antisera crossreacting with GsA metabolites. Most important, we demonstrate that patients' results are not reliably interchangeable among the methods.
Polyclonal radioimmunoassays
(RIAs) and an assortment of "in-house"-developed HPLC procedures have formerly been the laboratorian's only tools for therapeutic monitoring of cyclosporine (CsA). Unfortunately, these assays can be labor-intensive, 2-5) . Cross-reactivity of commercial polyclonal antisera with CsA metabolites distorts the analytical result and brings it into question because of the still-uncertain clinical role of the metabolites. Also to be considered when a "cyclosporine" assay is selected are test cost, time to obtain the result, and expertise required of technical personnel.
We have closely examined three commercially available assays and report here the performance of each. In an effort to minimize inconsistencies associated with isolation of plasma-specifically the hematocrit, temperature, and concentration-dependent distribution of CsA and its metabolites among plasma and cells (6) 
Materials and Methods
Immunoassays.
The three commercial polyclonal immunoassays we evaluated were as follows: 
Switzerland)
RIA with sheep antisera and a tritiated tracer, counted in a Tri-Carb liquid scintillation spectrephotometer (Packard Instruments, Downers Grove, IL). Quenching by hemoglobin was minimized by preparing calibrators in whole blood with hemoglobin concentrations approximately the same as those in the transplant-patients' specimens. All assays were performed according to manufacturers' instructions, in duplicate.
HPLC assay. We used a previously published HPLC procedure (7) for parent CsA, with slight modifications. To improve analytical recovery of CsA, we substituted a 500-mg BondElut Cyanopropyl cartridge solid-phase extraction column (Analytichem International, Harbor City, CA) for the 100-mg size and washed the final residue (reconstituted in mobile phase) with heptane before injecting it onto the analytical HPLC column (8). Overall, CVs were 6.9% and 4.5% at CsA concentrations of 102 and 450 g/L, respectively.
Control materials. The commercial materials we used for precision studies were the "low," "medium," and "high" concentrations of CsA in a simulated blood matrix, available in the commercial Abbott TDx kit, to evaluate the TDx method; and Lyphocheck I and II controls (BioRad, Anaheim, CA), commercially prepared with CsA in whole blood, to evaluate the Sandoz, Incstar, and HPLC methods.
Procedures. First, we determined the precision of the three immunoassays using the above-described controls. We also determined the analytical recovery of CsA in each immunoassay, assaying specimens of drug-free whole blood supplemented with pure CsA (from Sandoz Pharmaceuticals, East Hanover, NJ), added in dry form, to give concentrations of 0, 250, 500, 1000, and 2000 g/L.
To assess variations in test results among the three immunoassays and the HPLC, we obtainedby venipuncture whole-blood specimens from 210 post-transplant patients just before their next dose of CsA ("trough" values), added EDTA anticoagulant, and assayed with all methods. The specimens were selected to provide data over a clinically relevant concentration range. Most patients were concomitantly receiving prednisone, azothioprine, and OKT3 in addition to CsA.
To assess day-to-day trends in patients' results among the four procedures, we collected, as before, specimens from six patients: a 51-year-old man with a transplanted liver; a 42-year-old woman and a 51-year-old man, each with a transplanted heart; a 60-year-old man with a transplanted kidney; and a 35-year-old man and a 39-year-old man, each with a transplanted kidney and a transplanted pancreas. Each patient was monitored for at least 23 days. Table 1 lists precision data from the three polyclonal iminunoassays.
Results
Average overall CVs were 3.8%, 9.3%, and Trend comparisons (Figure 2 ) of daily serial specimens from six patients demonstrate that the four assays afford results that differ but roughly parallel one another. Relative differences are not consistently proportional for a patient's whole-blood specimens.
Occasionally, a result from one assay deviated substantially from the established intermethod trend. Usually, Abbott's FPIA measured more CsA-related material than did the other methods. For any single sample, intermethod "cyclosporme" results usually followed the pattern Abbott FPIA> Incstar RIA Sandoz RIA> HPLC (parent CsA).
DIscussion
Abbott Laboratories' FPIA for CsA and metabolites in whole blood offers distinct advantages over the Incstar and Sandoz polyclonal RIAs. Most notably, CVs were <4% with the TDx controls over the clinically significant concentration range. All three assays displayed acceptable analytical recovery (range 94% to 110.9%) of parent CsA from whole blood. Our initial recovery studies with the Abbott FPIA suggested a calibration problem: recovery ranged from 130% to 140%. We suspect incomplete solubilization of CsA in the simulated blood matrix used by the commercial Table 2 are not yet definitively known, and some of the metabolites may contribute to a patient's clinical outcome. In the haste to switch to the more specific methods, the potential usefulness of the polyclonal assays must not be overlooked. Sole reliance on assays specific for parent CsA may not be in the best interest of the patient. For example, Kunzendorfet al. (11) observed that increased concentrations of metabolites M17 and Ml contribute to immunosuppression and lower the incidence of rejection episodes. and have observed a positive correlation between increasing RIA/ HPLC ratios and enzyme activity in liver-transplant patients (3). In the following paper (9) we describe in depth the diverse cross-reactivity of commercial antisera with CsA metabolites and how this contributes to the analytical result.
Interpretation of patients' "trough" values for
